NEW YORK (GenomeWeb News) – Galapagos’ service division, BioFocus DPI, will make cell-based assays for Dart Neuroscience, which will use them in its drug discovery programs for brain disorders, Galapagos said today.
The three-year collaboration is potentially worth €4.1 million ($5.4 million) to Galapagos, the Mechelen, Belgium-based firm said.
In addition to providing the assays, BioFocus will perform high-throughput screening and hit expansion using its compound collections. It also will provide compound management for Dart over the three-year period.
San Diego-based Dart is privately held and was founded earlier this year.